SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

In its first public earnings call after its initial public offering in June, virtual chronic disease provider Omada Health reported $61 million in revenue, up 49% year over year. | The virtual chronic ...

Note that some links may require registration or subscription. The Trump administration is set to announce a proposed rule ...

Are local restaurants considering adding so called “Ozempic menus” to their menu mix, offering smaller entrée portions at ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...